Evidence map›Paper›PMID 28579232›Full record

ArticleVaccine2017

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Naif Khalaf Alharbi, Eriko Padron-Regalado, Craig P Thompson, Alexandra Kupke, Daniel Wells, Megan A Sloan, Keith Grehan, Nigel Temperton, Teresa Lambe, George Warimwe and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Naif Khalaf AlharbiThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Electronic address: harbina2@ngha.med.sa.
Eriko Padron-RegaladoThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Craig P ThompsonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; Department of Zoology, University of Oxford, Oxford, UK.
Alexandra KupkeInstitute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.
Daniel WellsThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Megan A SloanThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Keith GrehanViral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.
Nigel TempertonViral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK.
Teresa LambeThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
George WarimweThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Stephan BeckerInstitute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, TTU Emerging Infections, Germany.
Adrian V S HillThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Sarah C GilbertThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
University of Oxford · GBMedway School of Pharmacy · GBPhilipps University of Marburg · DE

Funding

Medical Research Council MC_PC_14111
6 · The paper itself

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.

Indexed as

Immunity, CellularAdenoviridaeAnimalsAntibodies, NeutralizingAntibodies, ViralCoronavirus InfectionsDose-Response Relationship, ImmunologicImmunity, HumoralImmunogenicity, VaccineMiceMiddle East Respiratory Syndrome CoronavirusSpike Glycoprotein, CoronavirusVaccinationVaccines, DNAVaccines, SyntheticViral VaccinesAntibodies, NeutralizingAntibodies, ViralMVA vaccineSpike Glycoprotein, CoronavirusVaccines, DNAVaccines, SyntheticViral VaccinesAdenoviral vectorChAdOx1CoronavirusImmunogenicityMERS-CoVMVAPoxviral vectorPrime boostVaccinationVaccine

Identifiers

PMID28579232
PMCPMC5516308
OpenAlexW2620690875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.